Thursday, March 25, 2021

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Clofazimine is a FDA-approved anti-leprosy (Mycobacterium disease) drug was effective for the inhibition SARS-CoV-2 and MERS-CoV-2 infections. This molecule was shown to inhibit both entry step and helicase activity during SARS-CoV-2 infection. Using hamster SARS-CoV-2 infection model, the therapeutic efficacy of clofazimine was confirmed, and a combination therapy with remdesivir was demonstrated to be more effective. Clofazimine is orally available drug, which is different from remdesivir.

No comments:

Post a Comment